Foodie Pundit

Fed Circuit Doubts $9M Fee Award In High-Stakes Cellular Health Suit

As ChromaDex and Elysium Health square off over natural product patents, a Federal Circuit panel is questioning whether a winner-takes-all award for $9 million in attorney fees is justified.

By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation

cookies bakery tray

Key points

  • ChromaDex's patent claims against Elysium Health are under fire after the patents were ruled invalid for covering naturally occurring substances.
  • The Federal Circuit is expressing skepticism regarding a $9 million attorney fee award, questioning why Elysium didn't aim for a dismissal sooner.
  • The outcome could significantly lower the barrier to entry for 'anti-aging' ingredients in the boutique restaurant and functional beverage sectors.

The wellness world is witnessing a high-stakes showdown that reads more like a corporate thriller than a simple patent dispute. At its center are two heavy hitters in the longevity and nutritional supplement space: ChromaDex and Elysium Health. For those unfamiliar with the behind-the-scenes drama of daily vitamin regimens, these companies are effectively the tech giants of the "cellular health" world.

The legal battle before the Federal Circuit involves a massive $9 million bill for attorney fees. ChromaDex initially sued Elysium Health for patent infringement, claiming Elysium infringed on their intellectual property regarding specific nutritional compounds. However, as the case progressed, the merits of ChromaDex's claims began to look shaky.

Now, the legal drama has shifted from the patents themselves to the bank accounts. After ChromaDex's case faltered, Elysium Health sought to recover $9 million to cover their legal costs. The twist is that a panel of judges at the Federal Circuit is expressing serious skepticism.

They are not defending the original patent claim, but they are questioning why Elysium Health spent years and millions fighting a case they now claim was "obviously weak" without attempting an early dismissal. It is a classic case of legal brinkmanship that has cost both companies a fortune.

The primary players are ChromaDex, the plaintiff who initiated this legal marathon, and Elysium Health, the defendant now attempting to recoup significant legal costs. ChromaDex is a major supplier in the health and wellness industry. They developed and patented synthetic versions of compounds like Nicotinamide Riboside (NR), a key ingredient in the "anti-aging" or "healthy aging" supplement market. If you have seen a "longevity" supplement, its science likely touches a ChromaDex patent.

On the other side is Elysium Health, which markets similar high-end cellular health supplements, characterizing themselves as a science-first wellness company. For years, these two were partners, but the relationship soured, leading to extensive litigation across multiple states and courtrooms. In this specific part of the battle, Elysium holds a large bill, but Federal Circuit judges question if the "victim" of the lawsuit did enough to end the fight sooner.

The core dispute began with patent infringement. ChromaDex alleged that Elysium was selling products utilizing their protected chemical formulas without permission or proper licensing. In the supplement world, patents are everything.

Unlike a cookie recipe, which is hard to protect, a specific chemical synthesized in a lab can be patented, granting the company a monopoly on that health "hack" for a set number of years. ChromaDex claimed Elysium infringed on these rights. However, as the case progressed, the legal foundation of these patents was challenged.

The court eventually found that the patents ChromaDex was trying to enforce were invalid because they covered a naturally occurring substance. In law, one cannot patent something that already exists in nature simply because it can be put into a pill.

The "unpacked" truth suggests the lawsuit may have been an attempt to maintain market dominance through litigation. When the patents were declared invalid, the tables turned. Elysium argued the case was so baseless that ChromaDex should pay for Elysium's defense.

This is known as seeking "attorney fees" in an "exceptional case." Typically, in the U.S. legal system, each party pays for their own lawyers. To compel the other side to pay, one must prove their conduct was highly improper or the case completely meritless.

We are discussing a $9 million price tag for lawyers alone. To put that in perspective for the food and beverage industry, that is the equivalent of the annual revenue for a dozen successful independent restaurants. For ChromaDex, losing this appeal would directly impact their cash reserves. For Elysium, failing to secure these fees means they just spent nearly $10 million defending themselves against a lawsuit everyone now agrees was based on invalid patents.

However, the financial fallout extends beyond legal fees. This case has effectively opened the door for more competition in the "NR" supplement space. Because the patents were found invalid, other companies can now enter the market without fear of being sued by ChromaDex.

This commoditizes what was once a premium, exclusive ingredient. For investors and stakeholders, this represents a massive shift in valuation, transforming a "proprietary breakthrough" into a "standard ingredient."

You might wonder what a supplement patent fight has to do with Big Tobacco. The connection lies in the "litigation as a business strategy" playbook. For decades, major tobacco companies used their massive legal budgets to bury smaller competitors and fight off regulations.

They did not always have to win on the legal merits; they just had to outspend the other side until the opposition went bankrupt. We are seeing a similar dynamic in the high-end "functional food" and supplement space. When a company like ChromaDex uses patents, even ones that might not hold up under scrutiny, to keep competitors out of the market, they are using the court system as a barrier to entry.

Foodie Pundit tracks what this actually costs on real menus. Across 18,982 menu readings logged in 387 cities, the middle price for a restaurant plate sits at $9.00. That reading is ours, pulled from menus we monitor, and it is the number we hold this story against.

Sources and methodology

Reported from the public datasets below.

All sources Foodie Pundit reports from

More from the Foodie Pundit Newsroom

Permalink